R&D

Pipeline

Ability Pharmaceuticals, SL has investigated the antiproliferative activity in a series of compounds, in in vitro models with several tumor cell lines. The mechanism causing the antiproliferative effect has also been characterized in several candidates.
 
ABTL0812 is currently in phase 2 clinical trials, as first line therapy in patients with endometrial or squamous lung cancer patients.The clinical trial is led by Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Institut Català d’Oncologia (ICO, Hospitalet, Badalona and Girona). The study also includes the INCLIVA (Valencia), Institut Gustave Roussy (Paris), Centre Léon-Bérard (Lyon), Institut Paoli-Calmettes (Marseille) and Hospital Universitario Virgen del Rocío (Sevilla). 


 

LATEST NEWS

19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
19.02.2018

News

AbilityPharma Announces FDA Approval of Phase 1/2 Trial of ABTL0812 for Patients with Advanced Metastatic Pancreatic Cancer + info
13.12.2017

News

AbilityPharma Announces FDA Approval of IND for Phase 2 Trial of ABTL0812 in Patients with Endometrial Cancer or Squamous Non-Small Cell Lung Cancer + info
05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG